HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) rose by over 5%, with the estimated year-on-year increase in net profit attributable to shareholders of 416.37%. The overseas market continues to expand.

Biocytogen Pharmaceuticals-B (02315) rose by more than 5%, up 5.09% to HK$55.75 as of the time of writing, with a trading volume of HK$6.6351 million. On the news front, on February 26th, Biocytogen Pharmaceuticals-B released its 2025 performance report, expecting the group's 2025 operating income to be approximately RMB 1.379 billion, a year-on-year increase of 40.63%; achieving a net profit attributable to the company's owners of RMB 173 million, a year-on-year increase of 416.37%; and achieving a net profit attributable to the company's owners excluding non-recurring gains and losses of RMB 116 million, a year-on-year increase of 405.39%. The group's total assets were RMB 3.724 billion, an increase of 54.20% from the beginning of the period; and the equity attributable to the owners of the company was RMB 2.175 billion, an increase of 160.76% from the beginning of the period. During the reporting period, the group's operating performance growth was mainly driven by the continued expansion of overseas markets, combined with the recovery and warming up of the domestic biopharmaceutical industry, resulting in high-speed growth in the group's operating income. In addition, the group has persisted in its strategy of driving performance growth through innovation, building core technological barriers through sustained high-intensity research and development investment to ensure that the business can remain stable at a high gross profit level. At the same time, the group continues to improve operational efficiency through lean management, thereby enhancing the group's profitability rapidly.